481 related articles for article (PubMed ID: 26541651)
1. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
3. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
[TBL] [Abstract][Full Text] [Related]
4. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
[No Abstract] [Full Text] [Related]
5. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
6. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer
Dong SH; Wang X; Tian SC; Ma NQ; Zhang XY; Liu Y; Zhang BL; Wu YJ
Pharmazie; 2018 May; 73(5):269-273. PubMed ID: 29724292
[TBL] [Abstract][Full Text] [Related]
7. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Jiang H; Zhu Y; Zhou Z; Xu J; Jin S; Xu K; Zhang H; Sun Q; Wang J; Xu J
Cancer Med; 2018 Mar; 7(3):869-882. PubMed ID: 29441724
[TBL] [Abstract][Full Text] [Related]
8. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway.
Zhu K; Peng Y; Hu J; Zhan H; Yang L; Gao Q; Jia H; Luo R; Dai Z; Tang Z; Fan J; Zhou J
Carcinogenesis; 2020 Apr; 41(2):130-138. PubMed ID: 31498866
[TBL] [Abstract][Full Text] [Related]
9. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
[TBL] [Abstract][Full Text] [Related]
10. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Bajbouj K; Ramakrishnan RK; Saber-Ayad M; Omar HA; Saheb Sharif-Askari N; Shafarin J; Elmoselhi AB; Ihmaid A; AlHaj Ali S; Alalool A; Abdullah R; Hamid Q
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200178
[TBL] [Abstract][Full Text] [Related]
11. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Jeon JY; Lee JS; Park ER; Shen YN; Kim MY; Shin HJ; Joo HY; Cho EH; Moon SM; Shin US; Park SH; Han CJ; Choi DW; Gu MB; Kim SB; Lee KH
Oncol Rep; 2018 Jul; 40(1):536-544. PubMed ID: 29749478
[TBL] [Abstract][Full Text] [Related]
12. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Tian Y; Yang W; Yang R; Zhang Q; Hao L; Bian E; Yang Y; Huang X; Wu Y; Zhang B
Toxicol Appl Pharmacol; 2022 Jan; 435():115829. PubMed ID: 34919946
[TBL] [Abstract][Full Text] [Related]
14. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells.
Qin X; Zhang H; Zhou X; Wang C; Zhang H; Zhang X; Ye L
Transl Res; 2007 Nov; 150(5):281-94. PubMed ID: 17964517
[TBL] [Abstract][Full Text] [Related]
15. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing β-catenin gene.
Wang B; Xunsun ; Liu JY; Yang D; Yang LL; Kong DX; Meng XW
Hepatogastroenterology; 2012; 59(114):515-8. PubMed ID: 22024040
[TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
Chung J; Karkhanis V; Baiocchi RA; Sif S
J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
[TBL] [Abstract][Full Text] [Related]
17. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
18. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
19. Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells.
Sipos A; Iván J; Bécsi B; Darula Z; Tamás I; Horváth D; Medzihradszky KF; Erdődi F; Lontay B
Sci Rep; 2017 Jan; 7():40590. PubMed ID: 28074910
[TBL] [Abstract][Full Text] [Related]
20. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells.
Ge L; Wang H; Xu X; Zhou Z; He J; Peng W; Du F; Zhang Y; Gong A; Xu M
J Cell Mol Med; 2020 Jan; 24(2):1969-1979. PubMed ID: 31851779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
